Alchemab Therapeutics is a biotechnology company focused on harnessing the power of the immune system to develop novel antibody therapeutics for hard-to-treat diseases. Their unique platform identifies naturally occurring protective antibodies from resilient individuals, such as long-term cancer survivors, using advanced deep learning and B cell sequencing techniques. With a strong emphasis on neurodegenerative conditions and oncology, Alchemab is building a diverse pipeline of therapeutics, supported by collaborations with patient groups and academic institutions. The company aims to transform drug discovery by leveraging insights from the immune system to create effective treatments for challenging diseases.

Beam Therapeutics is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing technology. This innovative approach allows for targeted genetic modifications without double-stranded DNA breaks, aiming to provide lifelong cures for patients with serious diseases. The company is at the forefront of genetic medicine, with a strong pipeline of therapies in development, including treatments for sickle cell disease. Beam's differentiation lies in its unique technology and commitment to rigorous research, positioning it as a leader in the rapidly evolving field of gene editing.

Carbon Biosciences develops genetic medicines for the treatment of devastating diseases. They develop their vector using industrial-scale viral production platforms and can be used to deliver a wide-range of therapeutic modalities.

Ceribell is revolutionizing electroencephalography (EEG) by providing a point-of-care EEG system that is FDA cleared and designed for rapid deployment in emergency and critical care settings. Their innovative technology allows healthcare providers to set up the EEG system in just six minutes, enabling faster diagnosis and treatment of seizures, including non-convulsive seizures. The proprietary Brain Stethoscope function simplifies EEG interpretation by converting brainwaves into sound, making it accessible for non-specialists. This approach not only improves patient outcomes but also reduces mortality and complications associated with delayed diagnosis. Ceribell's focus on efficiency and accessibility positions it strongly in the healthcare market, particularly in intensive care units and emergency departments.

CertiK is a pioneer in blockchain security, leveraging best-in-class AI technology to protect and monitor blockchain protocols and smart contracts. Founded in 2018 by professors from Yale University and Columbia University, CertiK’s mission is to secure the web3 world. CertiK applies cutting-edge innovations from academia to enterprise, enabling mission-critical applications to scale with safety and correctness.

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate, cretostimogene grenadenorepvec, is an investigational engineered oncolytic immunotherapy that has shown clinical benefit in BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC). The company aims to provide innovative therapies that enhance the quality of life for urologic cancer patients, positioning itself as a leader in the bladder cancer treatment market with a strong focus on patient-centered care and ongoing clinical trials.

Cobo is a trusted custody and wallet infrastructure provider that simplifies digital asset security. Founded in 2017, Cobo empowers organizations and developers to innovate and scale their blockchain businesses with ease. The company offers a comprehensive suite of wallet technologies, including custodial, MPC, smart contract, and exchange wallets, all designed to safeguard digital assets across multiple chains and tokens. With over $200 billion in transactions secured and more than 100 million wallets created, Cobo has established itself as a leader in the digital asset space, serving over 500 institutions worldwide. Their commitment to security is underscored by certifications such as SOC 2 Type 2 and ISO 27001, making them a reliable partner for businesses looking to navigate the complexities of digital asset management.

Cosmos is building the Internet of Blockchains, enabling a network of interconnected, sovereign, scalable, and secure blockchains. Their core products include the Cosmos SDK, IBC Protocol, Comet BFT, and Cosm Wasm, which provide developers with the tools to create fast and secure blockchain applications. With a focus on interoperability and flexibility, Cosmos allows businesses to launch and scale projects efficiently while maintaining control over their blockchain environments. The platform is supported by a growing community of developers and enterprises, positioning it as a leader in the blockchain ecosystem.

Darmiyan is a pioneering company focused on brain health, utilizing advanced AI and medical imaging to detect neurodegenerative diseases like Alzheimer's at early stages. Their flagship product, Brain See, is FDA-approved and combines MRI data with cognitive assessments to provide a prognosis score for patients with mild cognitive impairment. The technology is built on over 40 years of neuroscience research and aims to revolutionize brain health diagnostics and monitoring, making it accessible and non-invasive for patients and healthcare providers alike. With a strong emphasis on accuracy and integration, Darmiyan is positioned to significantly impact the healthcare landscape for brain diseases.

The DFINITY Foundation is a Swiss-based not-for-profit organization that develops the Internet Computer blockchain, enabling mass market Web3 services to run entirely on-chain. With a focus on chain-key cryptography, it allows for efficient, scalable smart contracts that serve web directly to end users. The organization boasts the largest R&D team in blockchain, comprising over 200 scientists and engineers, and aims to provide an alternative to traditional IT services. Its governance is managed by the Network Nervous System (NNS), a protocol-integrated DAO that employs liquid democracy, positioning DFINITY as a leader in the blockchain space.

Engine Biosciences is a biotech company that integrates machine learning and high-throughput biology to develop precision medicines. The company focuses on identifying key genetic interactions within complex disease networks to pinpoint targets and therapeutics for biomarker-defined patient populations. Their platform leverages extensive data and proprietary technologies to advance drug discovery and development, addressing a wide range of solid tumors and collaborating with partners in various therapeutic areas. With a strong foundation in synthetic and computational biology, Engine Biosciences aims to deliver impactful solutions for patients and enhance R&D processes.

Inf Stones is the world’s leading blockchain infrastructure provider, offering a comprehensive platform for launching and managing nodes, staking PoS tokens, and accessing APIs across over 80 blockchains. Founded in 2018, the company has established itself as a trusted partner for major brands in the blockchain industry, providing multi-cloud deployment and a fully decentralized service. With a focus on innovation and customer satisfaction, Inf Stones has built a robust ecosystem that supports developers in scaling Web3 applications efficiently. The company has achieved significant traction, reaching unicorn status and securing substantial funding, positioning itself as a key player in the blockchain infrastructure market.